Discover 524 paid clinical trials in Calgary, . Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Calgary runs one of the busiest research programs in western Canada, with hundreds of studies recruiting at any given time.The Arthur J.E. Child Comprehensive Cancer Centre opened in Calgary in October 2024, making cancer research the city's fastest-growing trial area. Roughly a third of Calgary's recruiting studies are in oncology, and the rest cluster around heart failure, kidney disease, and metabolic conditions, much of it run through the University of Calgary. The city is also unusual for the volume of paediatric research at Alberta Children's Hospital, so families often find studies here that are not available elsewhere in the province.
Filter
2
Filter results
Results: 524
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Calgary, Eugene OR, Walnut Creek CA, San Francisco CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06824467
Phase3, Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Calgary, Seattle WA, Portland OR, Salt Lake City UT,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06297226
Phase2, Recruiting
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
for
Esophageal Cancer
Location: Calgary
Sponsor: AHS Cancer Control Alberta
Sex: All
Age: 18 - 70+
Code: NCT05370144
Recruiting
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
for
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma,
Location: Calgary, Toronto
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 15+
Code: NCT07297667
Phase1, Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Calgary, Vancouver, Portland OR, Salt Lake City UT,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07258511
Phase3, Recruiting
Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis
for
Pneumonitis, Immune-related Adverse Event
Location: Calgary
Sponsor: AHS Cancer Control Alberta
Sex: All
Age: 18+
Code: NCT06860542
Phase2, Recruiting
Steroid Sparing in Immune Related Hepatitis (irH)
for
Hepatitis Immune
Location: Calgary
Sponsor: AHS Cancer Control Alberta
Sex: All
Age: 18+
Code: NCT05345847
Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
for
Renal Cell Carcinoma
Location: Calgary, San Antonio TX, Nashville TN, Philadelphia PA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07195682
Phase1, Recruiting
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
for
Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Location: Calgary, Vancouver, Vancouver WA, Happy Valley OR,
Sponsor: Genmab
Sex: Female
Age: 18+
Code: NCT07166094
Phase3, Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
for
Non-Small Cell Lung Cancer
Location: Calgary, Portland OR, Reno NV, Edwards CO, Orange CA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07100080
Phase2, Phase3, Recruiting
PROMIS and Mobility Evaluation in Sarcoma Patients
for
Sarcoma, Giant Cell Tumor of Bone
Location: Calgary
Sponsor: University of Calgary
Sex: All
Age: 18+
Code: NCT07227961
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma